EE200300355A - Neublastiini polümeerkonjugaadid ja meetodid nende kasutamiseks - Google Patents

Neublastiini polümeerkonjugaadid ja meetodid nende kasutamiseks

Info

Publication number
EE200300355A
EE200300355A EEP200300355A EEP200300355A EE200300355A EE 200300355 A EE200300355 A EE 200300355A EE P200300355 A EEP200300355 A EE P200300355A EE P200300355 A EEP200300355 A EE P200300355A EE 200300355 A EE200300355 A EE 200300355A
Authority
EE
Estonia
Prior art keywords
neublastin
methods
polymer conjugates
conjugates
polymer
Prior art date
Application number
EEP200300355A
Other languages
English (en)
Inventor
W. Y. Sah Dinah
Blake Pepinsky R.
Ann Borjack-Sjodin Paula
S. Miller Stephan
Rossomando Anthony
Original Assignee
Biogen, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen, Inc. filed Critical Biogen, Inc.
Publication of EE200300355A publication Critical patent/EE200300355A/et
Publication of EE05537B1 publication Critical patent/EE05537B1/et

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/4756—Neuregulins, i.e. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Obesity (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
EEP200300355A 2001-02-01 2002-01-25 Neublastiini polmeerkonjugaadid ja meetodid nende kasutamiseks EE05537B1 (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26607101P 2001-02-01 2001-02-01
PCT/US2002/002319 WO2002060929A2 (en) 2001-02-01 2002-01-25 Polymer conjugates of neublastin and methods of using same

Publications (2)

Publication Number Publication Date
EE200300355A true EE200300355A (et) 2003-10-15
EE05537B1 EE05537B1 (et) 2012-04-16

Family

ID=23013042

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200300355A EE05537B1 (et) 2001-02-01 2002-01-25 Neublastiini polmeerkonjugaadid ja meetodid nende kasutamiseks

Country Status (36)

Country Link
EP (2) EP1355936B1 (et)
JP (2) JP4259868B2 (et)
KR (2) KR100960063B1 (et)
CN (1) CN1500095B (et)
AR (1) AR035077A1 (et)
AT (1) ATE365748T1 (et)
AU (1) AU2002247037B2 (et)
BG (1) BG66393B1 (et)
BR (1) BR0206852A (et)
CA (1) CA2436407C (et)
CY (1) CY1106886T1 (et)
CZ (1) CZ20032080A3 (et)
DE (1) DE60220879T2 (et)
DK (1) DK1355936T3 (et)
EA (1) EA009771B1 (et)
EE (1) EE05537B1 (et)
ES (1) ES2289091T3 (et)
GE (1) GEP20063916B (et)
HK (1) HK1057759A1 (et)
HU (1) HU228973B1 (et)
IL (2) IL156941A0 (et)
IS (1) IS2867B (et)
MX (1) MXPA03006805A (et)
MY (1) MY143685A (et)
NO (1) NO332150B1 (et)
NZ (1) NZ527863A (et)
PL (1) PL211162B1 (et)
PT (1) PT1355936E (et)
RS (1) RS50857B (et)
SG (1) SG149685A1 (et)
SI (1) SI1355936T1 (et)
SK (1) SK288123B6 (et)
TR (1) TR200301208T2 (et)
UA (2) UA100967C2 (et)
WO (1) WO2002060929A2 (et)
ZA (1) ZA200305733B (et)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002060929A2 (en) * 2001-02-01 2002-08-08 Biogen, Inc. Polymer conjugates of neublastin and methods of using same
US7442370B2 (en) 2001-02-01 2008-10-28 Biogen Idec Ma Inc. Polymer conjugates of mutated neublastin
US7276580B2 (en) 2001-03-12 2007-10-02 Biogen Idec Ma Inc. Neurotrophic factors
AU2002250203B2 (en) * 2001-03-28 2006-08-10 Biogen Ma Inc. Use of neublastin polypeptides for treating neuropathic pain
CN1630530A (zh) * 2002-01-18 2005-06-22 比奥根艾迪克Ma公司 聚亚烷基聚合物及其用途
ES2351215T3 (es) * 2003-01-31 2011-02-01 Biogen Idec Ma Inc. Conjugados poliméricos de neublastina mutada.
CA2522364C (en) 2003-04-18 2014-12-09 Biogen Idec Ma Inc. Polymer-conjugated glycosylated neublastin
WO2004108760A2 (en) * 2003-06-10 2004-12-16 Nsgene A/S Improved secretion of neublastin
US7598059B2 (en) 2003-10-02 2009-10-06 Biogen Idec Ma Inc. Neublastin expression constructs
CA2577690C (en) * 2004-08-19 2013-08-06 Biogen Idec Ma Inc. Refolding transforming growth factor beta family proteins
SI1786454T1 (sl) 2004-08-19 2010-10-29 Biogen Idec Inc Variante neoblastina
TWI501774B (zh) 2006-02-27 2015-10-01 Biogen Idec Inc 神經性病症之治療
US20100056440A1 (en) * 2006-03-01 2010-03-04 Biogen Idec Ma Inc. Compositions and methods for administering gdnf ligand family proteins
AU2007296843C1 (en) 2006-09-15 2012-08-16 Creabilis Therapeutics S.P.A. Polymer conjugates of Box-A of HMGB1 and Box-A variants of HMGB1
CA2685686A1 (en) * 2007-05-01 2008-11-13 Biogen Idec Ma Inc. Neublastin polypeptides for use increasing vascularization in a tissue
CN104023804B (zh) * 2011-11-02 2017-05-24 弗·哈夫曼-拉罗切有限公司 超载和洗脱层析
RU2488635C1 (ru) * 2012-03-22 2013-07-27 Государственное бюджетное образовательное учреждение высшего профессионального образования Первый Московский государственный медицинский университет им. И.М. Сеченова Министерства здравоохранения и социального развития Российской Федерации (ГБОУ ВПО Первый МГМУ им. И.М. Сеченова Минздравсоцразвития Способ получения рекомбинантного антиангиогенного полипептида

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6472178B1 (en) * 1998-02-27 2002-10-29 Regeneron Pharmaceuticals, Inc. Nucleic acids encoding a modified ciliary neurotrophic factor and method of making thereof
US5770577A (en) * 1994-11-14 1998-06-23 Amgen Inc. BDNF and NT-3 polypeptides selectively linked to polyethylene glycol
US6593133B1 (en) * 1998-07-06 2003-07-15 Nsgene A/S Neurotrophic factors
WO2000034475A2 (en) * 1998-12-09 2000-06-15 Amgen Inc. Grnf4, a gdnf-related neurotrophic factor
WO2002060929A2 (en) * 2001-02-01 2002-08-08 Biogen, Inc. Polymer conjugates of neublastin and methods of using same

Also Published As

Publication number Publication date
DK1355936T3 (da) 2007-10-29
WO2002060929A2 (en) 2002-08-08
BG108111A (bg) 2004-12-30
HUP0500637A2 (hu) 2005-09-28
ZA200305733B (en) 2005-02-23
CA2436407C (en) 2011-08-30
CN1500095A (zh) 2004-05-26
CY1106886T1 (el) 2012-09-26
DE60220879T2 (de) 2008-03-06
NO20033441L (no) 2003-10-01
HU228973B1 (en) 2013-07-29
HK1057759A1 (en) 2004-04-16
KR100960063B1 (ko) 2010-05-31
EP1355936B1 (en) 2007-06-27
IL156941A (en) 2008-11-03
TR200301208T2 (tr) 2005-05-23
RS50857B (sr) 2010-08-31
UA100967C2 (ru) 2013-02-25
AR035077A1 (es) 2004-04-14
ATE365748T1 (de) 2007-07-15
UA82983C2 (ru) 2008-06-10
JP2005503763A (ja) 2005-02-10
SK288123B6 (sk) 2013-09-03
MXPA03006805A (es) 2003-11-13
KR20030074766A (ko) 2003-09-19
SI1355936T1 (sl) 2007-12-31
YU61003A (sh) 2006-05-25
HUP0500637A3 (en) 2010-01-28
EP1355936A2 (en) 2003-10-29
PL211162B1 (pl) 2012-04-30
MY143685A (en) 2011-06-30
GEP20063916B (en) 2006-09-11
JP4259868B2 (ja) 2009-04-30
EP1862475A1 (en) 2007-12-05
JP2009039135A (ja) 2009-02-26
IS6879A (is) 2003-07-17
CA2436407A1 (en) 2002-08-08
DE60220879D1 (de) 2007-08-09
NO20033441D0 (no) 2003-08-01
AU2002247037B2 (en) 2007-08-16
KR20080098662A (ko) 2008-11-11
SG149685A1 (en) 2009-02-27
IL156941A0 (en) 2004-02-08
NZ527863A (en) 2006-09-29
CZ20032080A3 (cs) 2003-10-15
PT1355936E (pt) 2007-09-28
NO332150B1 (no) 2012-07-09
JP4423338B2 (ja) 2010-03-03
IS2867B (is) 2014-02-15
EE05537B1 (et) 2012-04-16
CN1500095B (zh) 2010-06-16
SK9712003A3 (en) 2004-01-08
BR0206852A (pt) 2005-05-03
EA009771B1 (ru) 2008-04-28
BG66393B1 (bg) 2013-11-29
WO2002060929A3 (en) 2003-03-06
EA200300852A1 (ru) 2004-06-24
KR100872807B1 (ko) 2008-12-09
ES2289091T3 (es) 2008-02-01
PL372101A1 (en) 2005-07-11

Similar Documents

Publication Publication Date Title
CY2013032I1 (el) Συζυγη της εξενδινης-4 και η φαρμακευτικη τους χρηση
EE200300145A (et) Asa- ja polüasanaftalenüülkarboksamiidid ja farmatseutiline kompositsioon
NO20025580D0 (no) Medisinsk anordning
NO20040778L (no) Superabsorberende polymer
DK1284764T3 (da) Medicinsk apparat
NO20020235D0 (no) Medisinsk anordning
ATE355271T1 (de) Pharmazeutische zusammensetzung
EE200300355A (et) Neublastiini polümeerkonjugaadid ja meetodid nende kasutamiseks
EE200300311A (et) Ftalasinoon-piperidinoderivaadid, nende kasutamine ja ravim
EE200200626A (et) Antraniilamiidid ja nende kasutamine ravimitena
DE60234471D1 (de) Führung-in-führung-kathetersystem
EE200300193A (et) Asendatud bensimidasoolid, nende kasutamine ja ravim
FI20011671A0 (fi) Tuumorispesifiset oligosakkaridisekvenssit ja niiden käyttö
MA26998A1 (fr) Conjugues peg de hgt-nk4
DE60137941D1 (de) Polymerzusammensetzung
FI20001715A0 (fi) Rankoihin liittyvät järjestelyt ja menetelmät
FI20000818A0 (fi) Dermatologinen käyttö ja valmiste
DE60217390D1 (de) Bicalutamid enthaltende pharmazeutische zusammensetzung
DE60217539D1 (de) Leichtathletikschuh
DE60129238D1 (de) Pharmazeutische zusammensetzung
EE200300480A (et) Pregabaliini-laktoosi konjugaadid
DE10291905D2 (de) Pharmazeutische Zusammensetzung
DE10107261B4 (de) Pharmazeutische Zusammensetzung
FR2816398B3 (fr) Fronde perfectionnee
FIU20000507U0 (fi) Clinikit DiagnoPacks ja Openkit-konsepti

Legal Events

Date Code Title Description
HC1A Change of owner name
MM4A Lapsed by not paying the annual fees

Effective date: 20160125